Test a new HIV medicine with existing HIV treatment
Part of Infections clinical trials.
This Phase 3 study tests UB-421 added to a customized (optimized) set of existing HIV medicines for people with HIV that is resistant to multiple drugs. It may help reduce the virus more effectively when standard treatments have not been enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed HIV-1 infection.
- You have been on HIV antiretroviral treatment for at least 6 months.
- You have been on your current combination HIV regimen for at least 8 weeks and it is stable.
- You are not pregnant.
- You did not get a vaccine within 2 weeks before screening.
- You have never taken UB-421 before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether UB-421 combined with chidamide can shrink or control the “HIV reservoir,” the hidden HIV in the body that standard treatment may not fully eliminate. It’s mainly for people already on stable HIV medicines with very well-controlled viral levels.
This trial tests a new medicine, GS-0415, for people with HIV who are already on a stable treatment plan. It aims to see how safe and effective the new medicine is.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
This trial tests a combination of two experimental drugs designed to 'shock and kill' hidden HIV in your body. It is for people with HIV-1 subtype B who are on successful ART and want to explore a potential step toward a cure.
This trial tests a combination of two drugs that may 'wake up' hidden HIV in your body's cells, so that your immune system or other treatments can then eliminate it. The goal is to shrink the HIV reservoir that remains even when you're on antiretroviral therapy.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.